AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus

Journal of Neurochemistry

Volumn 88, Issue 5, 2004, Pages 1272-1282

  Gadalla, Anne E ^a   Pearson, Tim ^a   Currie, Ailsa J ^a   Dale, Nicholas ^b   Hawley, Simon A ^a   Sheehan, Mike ^c   Hirst, Warren ^c,d   Michel, Anton D ^c   Randall, Andrew ^c   Hardie, D Grahame ^a   Frenguelli, Bruno G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Neuroscience Research   (United States)

Author keywords

Acadesine; Adenosine; AICA riboside; AMPK; Ischaemia; Nucleoside transport

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NUCLEOSIDE TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; MALE; NEUROPROTECTION; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SYNAPTIC TRANSMISSION;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ENZYME ACTIVATION; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; MALE; MULTIENZYME COMPLEXES; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOTIDES; PROTEIN-SERINE-THREONINE KINASES; RATS; RECEPTORS, PURINERGIC P1; RIBONUCLEOSIDES; STRESS; SYNAPTIC TRANSMISSION;

ANIMALIA; HIPPOCAMPUS HIPPOCAMPUS; MAMMALIA;

EID: 10744230942     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02253.x     Document Type: Article

References (52)

1. Anderson W. W. and Collingridge G. L. (2001) The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 108, 71-83.
2. Baggott J. E., Vaughn W. H. and Hudson B. B. (1986) Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 236, 193-200.
3. Blazquez C., Geelen M. J., Velasco G. and Guzman M. (2001) The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett. 489, 149-153.
4. Blazquez C., Woods A., de Ceballos M. L., Carling D. and Guzman M. (1999) The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes. J. Neurochem. 73, 1674-1682.
5. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Brown A. J., Dyos S. L., Whiteway M. S. et al. (2000) Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein α-subunit chimeras. Yeast 16, 11-22.
7. Brundege J. M. and Dunwiddie T. V. (1997) Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv. Pharmacol. 39, 353-391.
8. Clough-Helfman C. and Phillis J. W. (1990) 5-Aminoimidazole-4-carboxamide riboside (AICAr) administration reduces cerebral ischemic damage in the Mongolian gerbil. Brain Res. Bull. 25, 203-206.
9. Corton J. M., Gillespie J. G., Hawley S. A. and Hardie D. G. (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565.
10. Culmsee C., Monnig J., Kemp B. E. and Mattson M. P. (2001) AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 17, 45-58.
11. Dale N., Pearson T. and Frenguelli B. G. (2000) Direct measurement of adenosine release during hypoxia in the CAI region of the rat hippocampal slice. J. Physiol. 526, 143-155.
12. Dale S., Wilson W. A., Edelman A. M. and Hardie D. G. (1995) Similar substrate recognition motifs for mammalian AMP-activated protein kinase, higher plant HMG-CoA reductase kinase-A, yeast SNF1, and mammalian calmodulin-dependent protein kinase I. FEBS Lett. 361, 191-195.
13. Davis K. A., Fabian T. C., Ragsdale D. N., Trenthem L. L. and Proctor K. G. (2000) Endogenous adenosine and secondary injury after chest trauma. J. Trauma 49, 892-898.
14. Dunwiddie T. V. (1999) Adenosine and suppression of seizures. Adv. Neurol. 791 1001-1010.
15. Dunwiddie T. V. and Diao L. (1994) Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J. Pharmacol. Exp. Ther. 268, 537-545.
16. 1 receptor-mediated responses in rat hippocampus. J. Neurosci. 17, 607-614.
17. Fryer L. G., Parbu-Patel A. and Carling D. (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232.
18. Gidday J. M., Fitzgibbons J. C., Shah A. R., Kraujalis M. J. and Park T. S. (1995) Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Pediatr. Res. 38, 306-311.
19. Halseth A. E., Ensor N. J., White T. A., Ross S. A. and Gulve E. A. (2002) Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem. Biophys. Res. Commun. 294, 798-805.
20. Hardie D. G. and Carling D. (1997) The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur. J. Biochem. 246, 259-273.
21. Hardie D. G., Carling D. and Carlson M. (1998) The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 821-855.
22. Hardie D. G. and Hawley S. A. (2001) AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23, 1112-1119.
23. Hardie D. G., Salt I. P. and Davies S. P. (2000) Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. Methods Mol. Biol. 99, 63-74.
24. Hawley S. A., Boudeau J., Reid J. L., Mustard K. J., Udd L., Makela T. P., Alessi D. R. and Hardie D. G. (2003) Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28.1-28.4.
25. Hawley S. A., Gadalla A. E., Olsen G. S. and Hardie D. G. (2002) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420-2425.
26. Kawahara N., Ide T., Saito N., Kawai K. and Kirino T. (1998) Propentofylline potentiates induced ischemic tolerance in gerbil hippocampal neurons via adenosine receptor. J. Cereb. Blood Flow Metab. 18, 472-475.
27. Kemp B. E., Mitchelhill K. I., Stapleton D., Michell B. J., Chen Z. P. and Witters L. A. (1999) Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 24, 22-25.
28. Lipton P. (1999) Ischemic cell death in brain neurons. Physiol. Rev. 79, 1431-1568.
29. 1 receptor inhibition. Neuroscience 112, 319-329.
30. Mangano D. T. (1997) Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA 277, 325-332.
31. Marangos P. J., Loftus T., Wiesner J., Lowe T., Rossi E., Browne C. E. and Gruber H. E. (1990) Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia 31, 239-246.
32. Marsin A. S., Bertrand L., Rider M. H., Deprez J., Beauloye C., Van den Vincent M. F. B. G., Carling D. and Hue L. (2000) Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 10, 1247-1255.
33. Marsin A. S., Bouzin C., Bertrand L. and Hue L. (2002) The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J. Biol. Chem. 277, 30778-30783.
34. Matot I. and Jurim O. (2001) The protective effect of acadesine on lung ischemia-reperfusion injury. Anesth. Analg. 92, 590-595.
35. McDonnell J., Latif M. L., Rees E. S., Bevan N. J. and Hill S. J. (1998) Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human β2-adrenoceptor. Br. J. Pharmacol. 125, 717-726.
36. Melton S. M., Moomey C. B. Jr, Ragsdale D. N., Trenthem L. L., Croce M. A., Fabian T. C. and Proctor K. G. (1999) Acadesine during fluid resuscitation from shock and abdominal sepsis. Crit. Care Med. 27, 565-575.
37. de Mendonça A., Sebastiao A. M. and Ribeiro J. A. (2000) Adenosine: does it have a neuroprotective role after all? Brain Res. Rev. 33, 258-274.
38. Mullane K. (1993) Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc. Res. 27, 43-47.
39. Musi N., Hirshman M. F., Nygren J. et al. (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51, 2074-2081.
40. Nawarskas J. J. (1999) Acadesine: a unique cardioprotective agent for myocardial ischemia. Heart Dis. 1, 255-260.
41. Pearson T., Nuritova F., Caldwell D., Dale N. and Frenguelli B. G. (2001) A depletable pool of adenosine in area CAI of the rat hippocampus. J. Neurosci. 21, 2298-2307.
42. Phillis J. W., O'Regan M. H., Estevez A. Y., Song D. and VanderHeide S. J. (1996) Cerebral energy metabolism during severe ischemia of varying duration and following reperfusion. J. Neurochem. 67, 1525-1531.
43. Picano E. and Abbracchio M. P. (1998) European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation? Trends Pharmacol. Sci. 19, 14-16.
44. Ragsdale D. N. and Proctor K. G. (2000) Acadesine and intestinal barrier function after hemorrhagic shock and resuscitation. Crit. Care Med. 28, 3876-3884.
45. Ribeiro J. A., Sebastiao A. M. and de Mendonça A. (2002) Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 68, 377-392.
46. Song X. M., Fiedler M., Galuska D., Ryder J. W., Fernstrom M., Chibalin A. V., Wallberg-Henriksson H. and Zierath J. R. (2002) 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 45, 56-65.
47. Thom J. A. and Jarvis S. M. (1996) Adenosine transporters. Gen. Pharmacol. 27, 613-620.
48. Turnley A. M., Stapleton D., Mann R. J., Witters L. A., Kemp B. E. and Bartlett P. F. (1999) Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J. Neurochem. 72, 1707-1716.
49. White T. D. (1996) Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. Eur J. Pharmacol. 303, 27-38.
50. Woods A., Salt I., Scott J., Hardie D. G. and Carling D. (1996) The α1 and α2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 397, 347-351.
51. Zhang G., Franklin P. H. and Murray T. F. (1993) Manipulation of endogenous adenosine in the rat pre-piriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther. 264, 1415-1424.
52. Zhou G., Myers R., Li Y. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174.